{"id":50623,"date":"2025-12-13T22:49:09","date_gmt":"2025-12-13T14:49:09","guid":{"rendered":"https:\/\/flcube.com\/?p=50623"},"modified":"2025-12-13T22:49:10","modified_gmt":"2025-12-13T14:49:10","slug":"bk-corporation-debuts-on-hkex-in-900m-ipo-backed-by-burn-drug-pipeline","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=50623","title":{"rendered":"B&amp;K Corporation Debuts on HKEX in $900M IPO Backed by Burn Drug Pipeline"},"content":{"rendered":"\n<p><strong>B&amp;K Corporation Limited<\/strong> (HKG: 2396) officially listed on the <strong>Hong Kong Stock Exchange<\/strong> today, offering <strong>17,648,800 shares<\/strong> at a maximum price of <strong>HK$51 per share<\/strong>, successfully raising over <strong>HK$900\u202fmillion<\/strong> (\u2248\u202fUS$115\u202fM). The biopharmaceutical company, founded in 2012, focuses on protein\u2011based therapies for unmet medical needs.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-ipo-details\">IPO Details<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Details<\/th><\/tr><\/thead><tbody><tr><td><strong>Exchange<\/strong><\/td><td>Hong Kong Stock Exchange (HKEX)<\/td><\/tr><tr><td><strong>Shares Offered<\/strong><\/td><td>17,648,800 shares (global offering)<\/td><\/tr><tr><td><strong>Maximum Price<\/strong><\/td><td>HK$51 per share<\/td><\/tr><tr><td><strong>Total Raise<\/strong><\/td><td>&gt;\u202fHK$900\u202fmillion (\u2248\u202fUS$115\u202fM)<\/td><\/tr><tr><td><strong>Ticker<\/strong><\/td><td>2396.HK<\/td><\/tr><tr><td><strong>Listing Date<\/strong><\/td><td>12\u202fDec\u202f2025<\/td><\/tr><tr><td><strong>Use of Proceeds<\/strong><\/td><td>Advance Pro\u2011101 programs to Phase\u202fIII; expand manufacturing; fund pipeline expansion<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-company-overview\">Company Overview<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Founded<\/th><th>Focus<\/th><th>Technology<\/th><\/tr><\/thead><tbody><tr><td><strong>2012<\/strong><\/td><td>Protein drugs for indications with unmet needs<\/td><td>Recombinant protein platform<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-core-pipeline\">Core Pipeline<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Asset<\/th><th>Indication<\/th><th>Stage<\/th><th>Key Data<\/th><\/tr><\/thead><tbody><tr><td><strong>Pro\u2011101\u20111<\/strong><\/td><td>Deep second\u2011degree burns\/scalds<\/td><td>Phase\u202fIIb complete<\/td><td>Statistical analysis finalized<\/td><\/tr><tr><td><strong>Pro\u2011101\u20111<\/strong><\/td><td>Superficial second\u2011degree burns\/scalds<\/td><td>Phase\u202fIIb complete<\/td><td>Last patient finished; data pending<\/td><\/tr><tr><td><strong>Pro\u2011101\u20112<\/strong><\/td><td>Diabetic foot ulcers<\/td><td>Phase\u202fII ongoing<\/td><td>Enrollment continues<\/td><\/tr><tr><td><strong>Other Candidates<\/strong><\/td><td>Undisclosed indications<\/td><td>Discovery\/pre\u2011clinical<\/td><td>8 additional assets<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-opportunity\">Market Opportunity<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Indication<\/th><th>Target Market<\/th><th>Key Driver<\/th><\/tr><\/thead><tbody><tr><td><strong>Burns (China)<\/strong><\/td><td>~\u202f1.5\u202fmillion hospitalizations annually<\/td><td>Limited effective protein therapies; Pro\u2011101\u20111 addresses wound healing<\/td><\/tr><tr><td><strong>Diabetic Foot Ulcers<\/strong><\/td><td>15\u201125% of diabetic patients develop DFU<\/td><td>High unmet need for advanced wound\u2011healing agents<\/td><\/tr><tr><td><strong>Peak Sales Forecast (Pro\u2011101\u20111)<\/strong><\/td><td><strong>\u00a52\u20113\u202fbillion<\/strong> (\u2248\u202fUS$280\u2011420\u202fM) by 2033<\/td><td>Assumes 20\u201125% share of severe burn segment post\u2011approval<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-implications\">Strategic Implications<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Capital Infusion:<\/strong> HK$900\u202fM raise extends runway through <strong>2027<\/strong>, funding Pro\u2011101\u20111 Phase\u202fIII initiation and Pro\u2011101\u20112 trial completion.<\/li>\n\n\n\n<li><strong>Platform Validation:<\/strong> Successful IPO demonstrates investor confidence in <strong>protein drug platform<\/strong> and <strong>late\u2011stage burn asset<\/strong> in a market lacking innovative treatments.<\/li>\n\n\n\n<li><strong>Pipeline Expansion:<\/strong> Proceeds will support advancement of <strong>8 additional candidates<\/strong>, potentially broadening into <strong>regenerative medicine and chronic wound care<\/strong>.<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding B&amp;K\u2019s use of IPO proceeds, clinical timelines, and market penetration for Pro\u2011101 programs. Actual results may differ due to clinical risks, regulatory delays, or competitive responses.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/2025121200082.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 2025121200082.\"><\/object><a id=\"wp-block-file--media-795818bb-c002-46cb-880d-aec6d70b0a88\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/2025121200082.pdf\">2025121200082<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/2025121200082.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-795818bb-c002-46cb-880d-aec6d70b0a88\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>B&amp;K Corporation Limited (HKG: 2396) officially listed on the Hong Kong Stock Exchange today, offering&#8230;<\/p>\n","protected":false},"author":1,"featured_media":50625,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[2284,4500,72],"class_list":["post-50623","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-bk-corporation","tag-hkg-2396","tag-ipo"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>B&amp;K Corporation Debuts on HKEX in $900M IPO Backed by Burn Drug Pipeline - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"B&amp;K Corporation Limited (HKG: 2396) officially listed on the Hong Kong Stock Exchange today, offering 17,648,800 shares at a maximum price of HK$51 per share, successfully raising over HK$900\u202fmillion (\u2248\u202fUS$115\u202fM). The biopharmaceutical company, founded in 2012, focuses on protein\u2011based therapies for unmet medical needs.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=50623\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"B&amp;K Corporation Debuts on HKEX in $900M IPO Backed by Burn Drug Pipeline\" \/>\n<meta property=\"og:description\" content=\"B&amp;K Corporation Limited (HKG: 2396) officially listed on the Hong Kong Stock Exchange today, offering 17,648,800 shares at a maximum price of HK$51 per share, successfully raising over HK$900\u202fmillion (\u2248\u202fUS$115\u202fM). The biopharmaceutical company, founded in 2012, focuses on protein\u2011based therapies for unmet medical needs.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=50623\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-12-13T14:49:09+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-12-13T14:49:10+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/1305-1.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50623#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50623\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"B&amp;K Corporation Debuts on HKEX in $900M IPO Backed by Burn Drug Pipeline\",\"datePublished\":\"2025-12-13T14:49:09+00:00\",\"dateModified\":\"2025-12-13T14:49:10+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50623\"},\"wordCount\":328,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50623#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/1305-1.webp\",\"keywords\":[\"B&amp;K Corporation\",\"HKG: 2396\",\"IPO\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=50623#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50623\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=50623\",\"name\":\"B&amp;K Corporation Debuts on HKEX in $900M IPO Backed by Burn Drug Pipeline - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50623#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50623#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/1305-1.webp\",\"datePublished\":\"2025-12-13T14:49:09+00:00\",\"dateModified\":\"2025-12-13T14:49:10+00:00\",\"description\":\"B&K Corporation Limited (HKG: 2396) officially listed on the Hong Kong Stock Exchange today, offering 17,648,800 shares at a maximum price of HK$51 per share, successfully raising over HK$900\u202fmillion (\u2248\u202fUS$115\u202fM). The biopharmaceutical company, founded in 2012, focuses on protein\u2011based therapies for unmet medical needs.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50623#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=50623\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50623#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/1305-1.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/1305-1.webp\",\"width\":1080,\"height\":608,\"caption\":\"B&K Corporation Debuts on HKEX in $900M IPO Backed by Burn Drug Pipeline\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50623#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"B&amp;K Corporation Debuts on HKEX in $900M IPO Backed by Burn Drug Pipeline\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"B&amp;K Corporation Debuts on HKEX in $900M IPO Backed by Burn Drug Pipeline - Insight, China&#039;s Pharmaceutical Industry","description":"B&K Corporation Limited (HKG: 2396) officially listed on the Hong Kong Stock Exchange today, offering 17,648,800 shares at a maximum price of HK$51 per share, successfully raising over HK$900\u202fmillion (\u2248\u202fUS$115\u202fM). The biopharmaceutical company, founded in 2012, focuses on protein\u2011based therapies for unmet medical needs.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=50623","og_locale":"en_US","og_type":"article","og_title":"B&amp;K Corporation Debuts on HKEX in $900M IPO Backed by Burn Drug Pipeline","og_description":"B&K Corporation Limited (HKG: 2396) officially listed on the Hong Kong Stock Exchange today, offering 17,648,800 shares at a maximum price of HK$51 per share, successfully raising over HK$900\u202fmillion (\u2248\u202fUS$115\u202fM). The biopharmaceutical company, founded in 2012, focuses on protein\u2011based therapies for unmet medical needs.","og_url":"https:\/\/flcube.com\/?p=50623","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-12-13T14:49:09+00:00","article_modified_time":"2025-12-13T14:49:10+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/1305-1.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=50623#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=50623"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"B&amp;K Corporation Debuts on HKEX in $900M IPO Backed by Burn Drug Pipeline","datePublished":"2025-12-13T14:49:09+00:00","dateModified":"2025-12-13T14:49:10+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=50623"},"wordCount":328,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=50623#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/1305-1.webp","keywords":["B&amp;K Corporation","HKG: 2396","IPO"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=50623#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=50623","url":"https:\/\/flcube.com\/?p=50623","name":"B&amp;K Corporation Debuts on HKEX in $900M IPO Backed by Burn Drug Pipeline - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=50623#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=50623#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/1305-1.webp","datePublished":"2025-12-13T14:49:09+00:00","dateModified":"2025-12-13T14:49:10+00:00","description":"B&K Corporation Limited (HKG: 2396) officially listed on the Hong Kong Stock Exchange today, offering 17,648,800 shares at a maximum price of HK$51 per share, successfully raising over HK$900\u202fmillion (\u2248\u202fUS$115\u202fM). The biopharmaceutical company, founded in 2012, focuses on protein\u2011based therapies for unmet medical needs.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=50623#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=50623"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=50623#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/1305-1.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/1305-1.webp","width":1080,"height":608,"caption":"B&K Corporation Debuts on HKEX in $900M IPO Backed by Burn Drug Pipeline"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=50623#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"B&amp;K Corporation Debuts on HKEX in $900M IPO Backed by Burn Drug Pipeline"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/1305-1.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/50623","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=50623"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/50623\/revisions"}],"predecessor-version":[{"id":50627,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/50623\/revisions\/50627"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/50625"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=50623"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=50623"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=50623"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}